Evidence map›Paper›PMID 38673941›Full record

ArticleInternational journal of molecular sciences2024

Smooth-Muscle-Cell-Specific Deletion of CD38 Protects Mice from AngII-Induced Abdominal Aortic Aneurysm through Inhibiting Vascular Remodeling.

Zhen-Ping Yu, Yi-Kai Wang, Xiao-Yu Wang, Li-Na Gong, Hui-Lan Tan, Mei-Xiu Jiang, Ling-Fang Wang, Guan-Hui Yu, Ke-Yu Deng, Hong-Bo Xin

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhen-Ping YuThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Yi-Kai WangThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.ORCID 0000-0003-4167-7264
Xiao-Yu WangThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Li-Na GongThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Hui-Lan TanThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Mei-Xiu JiangThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Ling-Fang WangThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Guan-Hui YuThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Ke-Yu DengThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Hong-Bo XinThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Nanchang University · CN

Funding

Jiangxi Provincial Department of Science and Technology 20212BCJ23043National Natural Science Foundation of China 81760140National Natural Science Foundation of China 81873659National Natural Science Foundation of China 81970256National Natural Science Foundation of China 82000354National Natural Science Foundation of China 82270302the National Key Research and development Program of China 2022YFA1104304
6 · The paper itself

Abstract

Abdominal aortic aneurysm (AAA) is a serious vascular disease which is associated with vascular remodeling. CD38 is a main NAD

Indexed as

ADP-ribosyl Cyclase 1Angiotensin IIAortic Aneurysm, AbdominalMice, KnockoutMyocytes, Smooth MuscleVascular RemodelingAnimalsDisease Models, AnimalMaleMembrane GlycoproteinsMiceMice, Inbred C57BLMuscle, Smooth, VascularMyosin Heavy ChainsSignal TransductionADP-ribosyl Cyclase 1Angiotensin IICd38 protein, mouseMembrane GlycoproteinsMyosin Heavy Chainsabdominal aortic aneurysmCD38phenotypic switchingsirtuinsvascular smooth muscle cells

Identifiers

PMID38673941
PMCPMC11049988
OpenAlexW4394806748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.